Symphony GenIsis Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Symphony GenIsis General Information

Description

Developer of cholesterol-lowering and diabetic drugs. The company's clinical programs include ISIS 301012, an antisense drug, which inhibits a protein for the synthesis and transport of the bad cholesterol involved in heart disease; Glucagon receptor, a cellular receptor for glucagon, one of the counter-regulatory hormones that oppose the action of insulin and helps maintain normal blood glucose levels; and The glucocorticoid receptor, which is an intracellular protein that serves as the receptor for the steroid hormones of the glucocorticoid family. The company operates as a subsidiary of ISIS Pharmaceuticals.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Food Products
Corporate Office
  • 7361 Calhoun Place
  • Suite 325
  • Rockville, MD 20855
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Symphony GenIsis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Symphony GenIsis‘s full profile, request access.

Request a free trial

Symphony GenIsis Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Symphony GenIsis‘s full profile, request access.

Request a free trial

Symphony GenIsis FAQs

  • Who is the founder of Symphony GenIsis?

    Neil Sandler is the founder of Symphony GenIsis.

  • Where is Symphony GenIsis headquartered?

    Symphony GenIsis is headquartered in Rockville, MD.

  • What industry is Symphony GenIsis in?

    Symphony GenIsis’s primary industry is Pharmaceuticals.

  • Is Symphony GenIsis a private or public company?

    Symphony GenIsis is a Private company.

  • What is the current valuation of Symphony GenIsis?

    The current valuation of Symphony GenIsis is 00000.

  • What is Symphony GenIsis’s current revenue?

    The current revenue for Symphony GenIsis is 000000.

  • Who are Symphony GenIsis’s investors?

    PineBridge Investments and Symphony Capital have invested in Symphony GenIsis.

  • When was Symphony GenIsis acquired?

    Symphony GenIsis was acquired on 27-Sep-2007.

  • Who acquired Symphony GenIsis?

    Symphony GenIsis was acquired by Ionis Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »